Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability

Bibliography

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th edition. American Psychiatric Publishing, Inc.; Arlington, Virginia: 2000
   Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-28
   PubMed Web of Science ®Google Scholar
• Citrome L. Paliperidone: quo vadis? Int J Clin Pract 2007;61:653-62
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid 2008;2:261-71
   PubMedGoogle Scholar
• FDA. Drug Approval Package. Invega (Paliperidone) Extended-Release Tablets. 30 March 2007. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021999s000_TOC.cfm [Last accessed 16 January 2012]
   Google Scholar
• FDA. Drug Approval Package. Invega (Paliperidone) 3, 6, 9, 12 mg Extended-Release Tablets. 28 May 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022043_invega_toc.cfm [Last accessed 16 January 2012]
   Google Scholar
• Janssen Pharmaceuticals. Invega (paliperidone) Extended-Release Tablets. Available from: http://www.janssencns.com/invega-prescribing-information [Last accessed 14 February 2012]
   Google Scholar
• Kantrowitz JT, Citrome L. Schizoaffective disorder: a review of current research themes and pharmacological management. CNS Drugs 2011;25:317-31
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychoticInt J Clin Pract 2009;63:1237-48
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2010;64:707-18
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
   PubMed Web of Science ®Google Scholar
• Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat 2011;7:325-39
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses 2011;4:251-7
   PubMedGoogle Scholar
• Janssen Pharmaceuticals. Invega Sustenna (paliperidone palmitate) Extended-Release Injectable Suspension for intramuscular use. Available from: http://www.janssencns.com/sustenna-prescribing-information [Last accessed 06 March 2012]
   Google Scholar
• Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence 2009;3:345-55
   PubMed Web of Science ®Google Scholar
• Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009;63:140-50
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Zhang L, Millen BA, A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011;31:349-55
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012;25:96-102
   PubMed Web of Science ®Google Scholar
• Betz R, Gerber T, Hosten E, Paliperidone: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]eth-yl}-9-hy-droxy-2-methyl-1,6,7,8,9,9a-hexa-hydro-pyrido[1,2-a]pyrimidin-4-one. Acta Crystallogr Sect E Struct Rep Online 2011;67(Pt 11):o2945-6
   Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl's essential psychopharmacology. 3rd edition. Cambridge University Press; Cambridge: 2008
   Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(Suppl 11):6-14
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A, Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197:229-35
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L, Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009;49:1318-30
   PubMed Web of Science ®Google Scholar
• de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010;51:80-8
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-79
   PubMed Web of Science ®Google Scholar
• Si T, Shu L, Liu Y, Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. Hum Psychopharmacol 2010;25:404-9
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals. Risperdal (risperidone) tablets, oral solution, orally disintegrating tablets. Available from: http://www.risperdal.com/prescribing.html [Last accessed 05 March 2012]
   Google Scholar
• Berwaerts J, Cleton A, Herben V, The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009;42:158-63
   PubMed Web of Science ®Google Scholar
• Thyssen A, Cleton A, Talluri K, No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol 2009;24:532-9
   PubMed Web of Science ®Google Scholar
• Boom S, Thyssen A, Crauwels H, The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009;47:606-16
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M, Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry 2010;71:587-98
   PubMed Web of Science ®Google Scholar
• Canuso CM, Schooler N, Carothers J, Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clin Psychopharmacol 2010;30:487-95
   PubMed Web of Science ®Google Scholar
• Singh J, Robb A, Vijapurkar U, A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 2011;70:1179-87
   PubMed Web of Science ®Google Scholar
• Kramer M, Simpson G, Maciulis V, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:6-14
   PubMed Web of Science ®Google Scholar
• Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010;70:1295-317
   PubMed Web of Science ®Google Scholar
• Gahr M, Kolle MA, Schonfeldt-Lecuona C, Paliperidone extended-release: does it have a place in antipsychotic therapy? Drug Des Dev Ther 2011;5:125-46
   PubMed Web of Science ®Google Scholar
• Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010;25:334-41
   PubMed Web of Science ®Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Rossenu S, A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010;24:1011-18
   PubMed Web of Science ®Google Scholar
• Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006;21:529-32
   PubMed Web of Science ®Google Scholar
• Knegtering R, Baselmans P, Castelein S, Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162:1010-12
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Fukui N, Watanabe J, QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol 2012;27:39-42
   PubMed Web of Science ®Google Scholar
• Hough DW, Natarajan J, Vandebosch A, Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2011;26:25-34
   PubMed Web of Science ®Google Scholar
• Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Gill JS, Pillai SK, Koh OH, Jambunathan S. Non-fatal paliperidone overdose: a case report. Turk Psikiyatri Derg 2010;21:331-4
   PubMed Web of Science ®Google Scholar
• Levine M, Lovecchio F, Tafoya P, Graham R. Paliperidone overdose with delayed onset of toxicity. Ann Emerg Med 2011;58:80-2
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012;15:107-18
   PubMed Web of Science ®Google Scholar
• Vieta E, Nuamah IF, Lim P, A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010;12:230-43
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Xu H, Nuamah I, Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012;136:e51-60
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Lane R, Nuamah IF, Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011;129:252-60
   PubMed Web of Science ®Google Scholar
• Ketter TA, Citrome L, Wang PW, Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand 2011;123:175-89
   PubMed Web of Science ®Google Scholar
• Seto K, Dumontet J, Ensom MHH. Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 2011;33:275-83
   PubMed Web of Science ®Google Scholar
• Nazirizadeh Y, Vogel F, Bader W. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010;66:797-803
   PubMed Web of Science ®Google Scholar
• Turkoz I, Bossie CA, Lindenmayer JP, Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry 2011;11:21
   PubMed Web of Science ®Google Scholar